Treatment with thrombolytic therapy may protect against these occurrence.

Treatment with thrombolytic therapy may protect against these occurrence , but can pose a bleeding. Therefore, Dr. Chang and colleagues sought to develop a safe, effective and affordable thrombolytic therapy for DVT.

– The results of the study showed that the blood flow throughout the deep venous system in 16 of the 20 patients during therapy with complete resolution of symptoms in 18 patients was restored after six months of anticoagulation. Alteplase was from the patient’s circulation system cleared within two hours after the treatment, making. Risk of bleeding There were no serious complications or bleeding during treatment , and no cases of post-thrombotic syndrome or recurrent bleeding during the follow-up of 3.4 years – .. Twenty patients with acute DVT were treated with direct intraclot lacing of the thrombus with a clot-dissolving agent called alteplase and full systemic anticoagulation. Alteplase binds to the clot, so that the method does not require a continuous infusion of the drug, as some thrombolytic therapies.The findings were published on 15 October 2008, a advance sales online to item in The New England Journal of Medicine of an international team workers from Japan, Spain, Norway and Italy.

In this case control study, Abenhaim and counterparts investigated whether frequency of physician visits visiting and pelvic examinations and the nature of health care professional an influence on the risk of by ovarian cancer was. They found out that women who not have an year doctor’s visit or pelvic exam and who had no routine care provider a higher risk from ovarian cancer were. That risk was the most marked at postmenopausal women. Although the studies detect determine that women who wanted healthcare regular basis and was had a normal doctor in the a reduced risk of getting ovarian cancer, general recommendation be that women who have mainly postmenopausal posts should be encouraged, A.